// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

B-cell depletion therapy with rituximab in RA: UCLH/UCL 20 years of experience

Caitlin M Norris-Grey - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

Effectiveness of adalimumab biosimilar switching: real world data from a London rheumatology centre

Shivanee Vigneswaran - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Adalimumab biosimilar

B cell-rich synovitis in early and established rheumatoid arthritis

Felice Rivellese - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Characterisation of human synovial tissue dendritic cells in rheumatoid arthritis patients

Aziza Elmesmari - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Rheumatoid arthritis

miR155

Baricitinib provides better pain relief across all disease activity levels compared with placebo and adalimumab in RA

Peter C Taylor (Presenter) - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

Utility of diagnostic ultrasound in a rheumatology podiatry clinic

Lisa Newcombe - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RA and multimorbidity in UK Biobank: association with all-cause mortality and major adverse cardiac events

Barbara Nicholl - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Third generation APCA improve prediction of clinical arthritis in at-risk individuals with positive second generation ACPA

Andrea Di Matteo - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Inflammatory Arthritis

N/A

Can ultrasound alone predict the need to treat ACPA positive individuals without synovitis?

Laurence M Duquenne - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Associations between clinical variables and psychological symptoms in RA: a network science perspective

Hsiu Yen Tung - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA

Karl Gaffney - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inflammatory Arthritis

N/A

Determining factors related to poor quality of life in patients with axSpA: results from the British Society for Rheumatology Biologics Register

Linda E Dean - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Relationship between symptoms and imaging in axSpA

Jodie Taylor - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Predicting non-response to biologic therapy amongst patients with axSpA: results from the British Society for Rheumatology Biologics Register

Linda E Dean - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pain, morning stiffness and fatigue in patients with active AS over 4 years

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

secukinumab

Working with axSpA: a qualitative study using the British Society for Rheumatology Biologics Register

Rosemary J Hollick - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study

Hasan Tahir - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

secukinumab

Pattern of mortality for patients with axSpA: a retrospective UK database analysis

Christopher L. I Morgan - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Treatment pathways for patients with axSpA: a retrospective UK database analysis

Christopher L. I Morgan - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

N/A

Secukinumab provides sustained improvements in tender and swollen joint counts: 5year results from the Phase 3 FUTURE 2 study

Iain McInnes - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

secukinumab

Copyright © 2026. QuantiNova All rights reserved